The global COVID-19 pandemic has affected the world in different ways, with many countries implementing lockdowns, border closures, and other movement and social restrictions. Within a very short space of time, the world went virtual. People began working from home, in-person business meetings were replaced by video calls, and businesses around the globe began their contingency planning. In the life sciences industry, for example, we saw the postponement of many clinical trials, and when we turn our attentions to the stakeholder engagement and value communication space, many of our customers found themselves being refused entry into hospitals and doctors surgeries. But, how are life sciences companies changing and adapting their stakeholder engagement strategies in response to COVID-19? Have the ways in which they communicate product value changed? How are field teams reaching customers and key stakeholders? To get answers to these questions, we surveyed a variety of professionals that are involved in stakeholder engagement and value communication. Respondents included board members, C-Level executives, and VPs, all the way through to key account and territory managers. As well as also being from a variety of countries – such as the U.S., Germany, Canada, and the UK – throughout key regions, participants were from companies ranging from established tier 1 pharma and medical device conglomerates to emerging startups. Once we’d accumulated the results, we then asked a few market access, stakeholder engagement and value communication experts to give their insight, and expand on some of the questions and key findings.
Certara’s Better Drug Development Process The drug development process is long and expensive with more failures than successes. At Certara, we support confident decision-making throughout the entire drug development process with our gold-standard software and technology-enabled services, helping our partners to reduce cycle times, lower costs, and improve outcomes for patients. In fact, eleven regulatory agencies worldwide have adopted our Phoenix™ PK/PD and/or Simcyp™ PBPK Simulator software platforms, including the US FDA and EMA. Our results speak for themselves. 90% of companies that received new drug approvals by the FDA in the past 6 years use our software or services.To learn more about Certara visit: www.Certara.com. To learn more about Basecase, visit: www.certara.com/evidence-access/basecase-value-communication-software/ Or contact us today: Email: sales@certara.com Phone: +49 3020143640